The estimated Net Worth of Steven B Ketchum is at least $6.34 Million dollars as of 31 January 2024. Dr Ketchum owns over 79,500 units of Amarin Corp stock worth over $401,811 and over the last 16 years he sold AMRN stock worth over $5,181,098. In addition, he makes $758,137 as Pres of R&D und Sr. VP and Chief Scientific Officer at Amarin Corp.
Dr has made over 39 trades of the Amarin Corp stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 79,500 units of AMRN stock worth $46,905 on 31 January 2024.
The largest trade he's ever made was selling 421,629 units of Amarin Corp stock on 27 January 2021 worth over $3,377,248. On average, Dr trades about 26,469 units every 83 days since 2008. As of 31 January 2024 he still owns at least 681,036 units of Amarin Corp stock.
You can see the complete history of Dr Ketchum stock trades at the bottom of the page.
Dr. Steven B. Ketchum is the Pres of R&D, Sr. VP and Chief Scientific Officer at Amarin Corp.
As the Pres of R&D und Sr. VP and Chief Scientific Officer of Amarin Corp, the total compensation of Dr Ketchum at Amarin Corp is $758,137. There are 6 executives at Amarin Corp getting paid more, with John Thero having the highest compensation of $8,929,540.
Dr Ketchum is 55, he's been the Pres of R&D und Sr. VP and Chief Scientific Officer of Amarin Corp since . There are 11 older and 5 younger executives at Amarin Corp. The oldest executive at Amarin Corp is Patrick O'Sullivan, 78, who is the Non-Executive Independent Director.
Steven's mailing address filed with the SEC is C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER, NJ, 08807.
Over the last 13 years, insiders at Amarin Corp have traded over $25,876,836 worth of Amarin Corp stock and bought 581,426 units worth $751,974 . The most active insiders traders include John F Thero, Steven B Ketchum und David M Stack. On average, Amarin Corp executives and independent directors trade stock every 10 days with the average trade being worth of $29,442. The most recent stock trade was executed by Aaron Berg on 2 August 2024, trading 160,000 units of AMRN stock currently worth $102,400.
amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.
Amarin Corp executives and other stock owners filed with the SEC include: